SEC Contract Filing

Filing Date: 2020-03-02

Document Content:
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>3
<FILENAME>exhibit1042ntuamendmen.htm
<DESCRIPTION>EXHIBIT 10.42
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
 <!-- Document created using Wdesk 1 -->
 <!-- Copyright 2020 Workiva -->
 <title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5CFAC0F2114A1C7E9BD287A00D14E73B"></a></div><div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.42</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Confidential PTC draft &#8211; November 11, 2019</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.</font></div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">License and Technology Transfer Agreement Amendment No. 2</font></div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(&#8220;Amendment No. 2&#8221;)</font></div><div style="line-height:130%;padding-bottom:10px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Effective Date: Dec. 1, 2019</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Parties to Agreement:</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">National Taiwan University&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(&#8220;Party A&#8221;)</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Professor Wuh-Liang (Paul) Hwu&#160;&#160;&#160;&#160;(&#8220;Party B&#8221;)</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PTC Therapeutics GT, Inc.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(&#8220;Party C&#8221;)</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, Party A and Party B entered in to a certain License and Technology Transfer Agreement with Agilis BioTherapeutics, LLC, NTU Contract No.: 104-I0TC-10, dated December 23, 2015 (the &#8220;Agreement&#8221;);</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, on February 4, 2017, Agilis BioTherapeutics, LLC, converted its corporate form and changed its name to Agilis BioTherapeutics Inc.; </font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, on August 23, 2018, PTC Therapeutics, Inc. acquired Agilis BioTherapeutics, Inc., via its wholly-owned subsidiary PTC Therapeutics Holdings, Inc., and on August 24, 2018, changed its name to PTC Therapeutics GT, Inc.;</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, PTC Therapeutics GT, Inc. (Party C) is now a wholly-owned affiliate of PTC Therapeutics, Inc. and the successor to all the rights and obligations of Agilis BioTherapeutics, LLC under the Agreement;</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, Party C is pursuing a regulatory strategy of direct pursuit of marketing approval for the first Licensed Product, and therefore will not conduct a Phase III study;</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, the Parties desire to amend the agreement to reflect this regulatory strategy and change the triggering event for payment of the former Phase III milestones;</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NOW, THEREFORE, the Parties hereby agree as Follows:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The first two sentences of Section 3.3 of the Agreement are deleted in their entirety.</font></div></td></tr></table><div style="line-height:130%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><ta